Bone marrow-derived mononuclear cells for peripheral vascular disease

This study assessed the safety of intramuscular injection of bone marrow-derived mononuclear cells for treatment of patients with critical limb ischemia. Cell treatment was found to be safe and posed fewer risks to the patients when compared to amputation. In addition, amputation-free survival at one-year was 86.3%, which suggests treatment efficacy.